JP2013545779A5 - - Google Patents

Download PDF

Info

Publication number
JP2013545779A5
JP2013545779A5 JP2013543710A JP2013543710A JP2013545779A5 JP 2013545779 A5 JP2013545779 A5 JP 2013545779A5 JP 2013543710 A JP2013543710 A JP 2013543710A JP 2013543710 A JP2013543710 A JP 2013543710A JP 2013545779 A5 JP2013545779 A5 JP 2013545779A5
Authority
JP
Japan
Prior art keywords
amino
imidazo
cyclopropyl
pyrazin
benzamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013543710A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013545779A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/072591 external-priority patent/WO2012080236A1/en
Publication of JP2013545779A publication Critical patent/JP2013545779A/ja
Publication of JP2013545779A5 publication Critical patent/JP2013545779A5/ja
Pending legal-status Critical Current

Links

JP2013543710A 2010-12-17 2011-12-13 過剰増殖性障害の治療におけるmps−1およびtkk阻害剤として使用するための6置換イミダゾピラジン Pending JP2013545779A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP10195699 2010-12-17
EP10195699.3 2010-12-17
EP10195635.7 2010-12-17
EP10195635 2010-12-17
EP11170158 2011-06-16
EP11170163 2011-06-16
EP11170158.7 2011-06-16
EP11170163.7 2011-06-16
PCT/EP2011/072591 WO2012080236A1 (en) 2010-12-17 2011-12-13 6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders

Publications (2)

Publication Number Publication Date
JP2013545779A JP2013545779A (ja) 2013-12-26
JP2013545779A5 true JP2013545779A5 (enExample) 2015-02-05

Family

ID=45218758

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013543710A Pending JP2013545779A (ja) 2010-12-17 2011-12-13 過剰増殖性障害の治療におけるmps−1およびtkk阻害剤として使用するための6置換イミダゾピラジン

Country Status (6)

Country Link
US (1) US20140135319A1 (enExample)
EP (1) EP2651945A1 (enExample)
JP (1) JP2013545779A (enExample)
CN (1) CN103429592A (enExample)
CA (1) CA2821819A1 (enExample)
WO (1) WO2012080236A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60100852A (ja) * 1984-09-28 1985-06-04 Hitachi Ltd 情報伝送方法
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
GB201212513D0 (en) * 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
WO2014020043A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
WO2014020041A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
JP6377068B2 (ja) 2012-11-16 2018-08-22 ユニバーシティ・ヘルス・ネットワーク ピラゾロピリミジン化合物
JP6159028B2 (ja) 2013-07-31 2017-07-05 ギリアード サイエンシーズ, インコーポレイテッド Syk阻害剤
EA029372B1 (ru) * 2013-11-15 2018-03-30 Юниверсити Хелс Нетуорк Пиразолопиримидиновые соединения
KR102421235B1 (ko) 2014-02-13 2022-07-15 인사이트 코포레이션 Lsd1 저해제로서 사이클로프로필아민
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
NZ723203A (en) 2014-02-13 2020-08-28 Incyte Corp Cyclopropylamines as lsd1 inhibitors
EP3392244A1 (en) 2014-02-13 2018-10-24 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
WO2016007731A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines and imidazopyrazines as lsd1 inhibitors
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
UA122688C2 (uk) 2015-04-03 2020-12-28 Інсайт Корпорейшн Гетероциклічні сполуки як інгібітори lsd1
EP3283642B1 (en) 2015-04-17 2023-10-11 Netherlands Translational Research Center Holding B.V. Prognostic biomarkers for ttk inhibitor chemotherapy
JP7427363B2 (ja) 2015-08-12 2024-02-05 インサイト・ホールディングス・コーポレイション Lsd1阻害剤の塩
US10166221B2 (en) 2016-04-22 2019-01-01 Incyte Corporation Formulations of an LSD1 inhibitor
AU2018253115B2 (en) 2017-04-12 2022-08-11 Edigene Biotechnology, Inc. Aryl hydrocarbon receptor antagonists and uses thereof
JP7412341B2 (ja) * 2017-10-31 2024-01-12 エディジーン バイオテクノロジー インコーポレイテッド 造血幹細胞および前駆細胞の増幅のための組成物および方法
HUE068695T2 (hu) * 2018-05-08 2025-01-28 Nippon Shinyaku Co Ltd Azabenzimidazol vegyületek és gyógyszerek
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
CA3115825A1 (en) * 2018-10-17 2020-04-23 Magenta Therapeutics, Inc. Methods of treating cancer with aryl hydrocarbon receptor antagonists
US12528813B2 (en) 2019-11-13 2026-01-20 Nippon Shinyaku Co., Ltd. Substituted imidazo[4,5-b]pyridines as M3 receptor PAMs

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
DE60317353T2 (de) * 2002-09-23 2008-08-28 Schering Corp. Imidazopyrazine als cdk-inhibitoren
US7576085B2 (en) * 2002-09-23 2009-08-18 Schering Corporation Imidazopyrazines as cyclin dependent kinase inhibitors
AU2003275031B2 (en) * 2002-09-23 2006-08-17 Schering Corporation Novel imidazopyrazines as cyclin dependent kinase inhibitors
US7186832B2 (en) 2003-02-20 2007-03-06 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
US7157460B2 (en) * 2003-02-20 2007-01-02 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
US7700773B2 (en) * 2005-09-09 2010-04-20 Schering Corporation 4-cyano, 4-amino, and 4-aminomethyl derivatives of pyrazolo[1,5-a]pyridines, pyrazolo[1,5-c]pyrimidines and 2H-indazole compounds and 5-cyano, 5-amino, and 5-aminomethyl derivatives of imidazo[1,2-a]pyridines, and imidazo[1,5-a]pyrazines as cyclin dependent kinase inhibitors
CA2628455A1 (en) 2005-11-10 2007-05-24 Merck Sharp & Dohme Corp. Imidazopyrazines as protein kinase inhibitors
TW200803863A (en) * 2005-11-10 2008-01-16 Schering Corp Method for inhibiting protein kinases
CA2654202A1 (en) 2006-06-06 2007-12-21 Schering Corporation Imidazopyrazines as protein kinase inhibitors
EP2471529A3 (en) * 2006-09-05 2012-10-10 Emory University Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof
EP2079746A2 (en) 2006-11-08 2009-07-22 Schering Corporation Imidazopyrazines as protein kinase inhibitors
GB0716292D0 (en) * 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
MX2010002115A (es) * 2007-08-23 2010-06-01 Aztrazeneca Ab 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos .proliferativos.
ES2547328T3 (es) 2009-04-29 2015-10-05 Bayer Intellectual Property Gmbh Imidazoquinoxalinas sustituidas
TW201107329A (en) * 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
JP5728683B2 (ja) 2009-09-04 2015-06-03 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH チロシンスレオニンキナーゼ阻害剤としての置換アミノキノキサリン
EP2343295A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridine derivates
EP2343294A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
ES2551407T3 (es) * 2010-03-18 2015-11-18 Bayer Intellectual Property Gmbh Imidazopirazinas
WO2011151259A1 (en) * 2010-06-01 2011-12-08 Bayer Pharma Aktiengesellschaft Substituted imidazopyrazines
WO2012080228A1 (en) * 2010-12-17 2012-06-21 Bayer Pharma Aktiengesellschaft 6-thio-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
EP2651944B1 (en) * 2010-12-17 2015-09-23 Bayer Intellectual Property GmbH Substituted 6-imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
CN103429591A (zh) * 2010-12-17 2013-12-04 拜耳知识产权有限责任公司 在治疗过度增殖性病症中用作mps-1和tkk抑制剂的6-取代的咪唑并吡嗪

Similar Documents

Publication Publication Date Title
JP2013515729A5 (enExample)
HRP20201337T1 (hr) Inhibitori lizin-specifične demetilaze-1
JP2013537174A5 (enExample)
JP2016523911A5 (enExample)
RU2507204C2 (ru) Положительные аллостерические модуляторы м1-рецепторов на основе пираниларилметилбензохиназолинона
CN111601593B (zh) P38激酶抑制剂降低dux4和下游基因表达以用于治疗fshd
HRP20240994T1 (hr) Spoj inhibitora jak i njegova uporaba
HRP20251479T1 (hr) Pesticidno aktivni kondenzirani biciklički heteroaromatski spojevi
SI3083586T1 (en) The new carboxamides, the process of their manufacture, the pharmaceutical preparations they contain and their use for the manufacture of medicinal products
SI3183247T1 (en) Aminopyrimidinyl compounds as inhibitors of JAK
JP2019523233A5 (enExample)
JP2006520805A5 (enExample)
JP2019504821A5 (enExample)
RU2016124176A (ru) Композиции тетрагидрохинолинов в качестве ингибиторов бромодомена вет
JP2011520908A5 (enExample)
HRP20160360T1 (hr) Supstituirani imidazopiridazini
JP2016528298A5 (enExample)
JP2012532931A5 (enExample)
JP2014521711A5 (enExample)
JP2013523884A5 (enExample)
RU2015152576A (ru) Производные индолин-2-она или пирролопиридин/пиримидин-2-она
JP2012501312A5 (enExample)
RU2015105249A (ru) Ингибиторы mtor киназы для онкологических показаний и заболеваний, связанных с mtor/pi3k/akt путем метаболизма
JP2014501269A5 (enExample)
JP2015500332A5 (enExample)